Ray Isabel K, Sobrin Lucia, Moorthy Ramana, Yeh Steven, Thorne Jennifer E, Shantha Jessica G
F.I. Proctor Foundation, University of California, San Francisco, California, USA.
Department of Ophthalmology, University of California, San Francisco, California, USA.
Ocul Immunol Inflamm. 2025 Jul;33(5):729-735. doi: 10.1080/09273948.2024.2380902. Epub 2024 Jul 29.
Due to lack of large randomized clinical trials to determine best practices in treating acute retinal necrosis (ARN), there is not a clear consensus amongst ophthalmologists on how to best manage this potentially blinding condition. The aim of this study is to survey common practice patterns and analyze the factors that affect ophthalmologists' management of ARN.
An anonymous survey was distributed to uveitis and retina specialists who are members of the American Uveitis Society (AUS) via email to query practice patterns regarding ARN. The survey included 22 questions with an additional 10 questions based on response. Survey question topics included demographic information, diagnostic testing, antiviral therapy, corticosteroids, and surgical procedures.
67 surveys were included for analysis. Most respondents (87%) always or frequently obtain intraocular aqueous fluid for diagnostic PCR testing. The majority of respondents would administer intravitreal antiviral injections to a unilateral immunocompetent ARN patient (67%), but would be even more likely to do so for a bilateral immunosuppressed ARN patient (87%). Respondents tend to treat ARN with systemic rather than local corticosteroids, with the majority (63%) of respondents initiating corticosteroid treatment 48 hours after treatment. Most respondents (79%) never perform a vitrectomy to manage ARN unless the patient has a retinal detachment or tear. The majority (63%) rarely or never perform prophylactic laser barricade, but may consider laser treatment if there is extensive retinal involvement.
Current practice patterns for diagnosis and management of ARN among AUS members generally align with the suggested practices outlined by the American Academy of Ophthalmology.
由于缺乏大型随机临床试验来确定急性视网膜坏死(ARN)的最佳治疗方法,眼科医生对于如何最佳管理这种可能导致失明的疾病尚未达成明确共识。本研究的目的是调查常见的治疗模式,并分析影响眼科医生对ARN治疗管理的因素。
通过电子邮件向美国葡萄膜炎学会(AUS)的葡萄膜炎和视网膜专科医生发放匿名调查问卷,以询问有关ARN的治疗模式。该调查包括22个问题,并根据回答增加了10个问题。调查问题主题包括人口统计学信息、诊断测试、抗病毒治疗、皮质类固醇和手术程序。
纳入67份调查问卷进行分析。大多数受访者(87%)总是或经常获取眼内房水进行诊断性聚合酶链反应(PCR)检测。大多数受访者会对单侧免疫功能正常的ARN患者进行玻璃体内抗病毒注射(67%),但对双侧免疫抑制的ARN患者更可能这样做(87%)。受访者倾向于用全身性而非局部性皮质类固醇治疗ARN,大多数受访者(63%)在治疗48小时后开始使用皮质类固醇治疗。大多数受访者(79%)除非患者发生视网膜脱离或撕裂,否则从不进行玻璃体切除术来治疗ARN。大多数受访者(63%)很少或从不进行预防性激光光凝,但如果视网膜广泛受累,可能会考虑激光治疗。
美国葡萄膜炎学会成员目前对ARN的诊断和治疗模式总体上与美国眼科学会概述的建议做法一致。